Preoperative Use of Intravenous Contrast Media Is Associated With Decreased Excellent Response Rates in Intermediate-Risk DTC Patients Who Subsequently Receive Total Thyroidectomy and Low-Dose RAI Therapy

Wei Lan 1,2*, Wang Renjie 1,2*, Wan Qichang 3, Teng Feiyue 1,2, Ma Qingjie 1,2* and Ji Bin 1,2*

1 Department of Nuclear Medicine, China-Japan Union Hospital of Jilin University, Changchun, China, 2 NHC Key Laboratory of Radiobiology, School of Public Health of Jilin University, Changchun, China, 3 Department of Nuclear Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

Purpose: To evaluate the impact of preoperative use of intravenous contrast media (ICM) on the excellent response (ER) rates in a cohort of intermediate-risk differentiated thyroid cancer (DTC) patients who received total thyroidectomy (TT) and low-dose radioactive iodine (RAI) therapy.

Methods: A total of 683 consecutive patients were retrospectively reviewed in a single center between August 2016 and August 2018. Patients were divided into ICM group (n = 532) and non-ICM group (n = 151). Intravenous contrast media patients were 1:1 propensity matched to non-ICM patients based on T stage, N stage, and urinary iodine. Risk-adjusted logistic regression models were constructed to assess the association between the use of ICM and ER rates.

Results: Intravenous contrast media patients had significantly higher T stage (P < 0.001), N stage (P < 0.001), urinary iodine (P < 0.001), and ps-Tg (P = 0.042) than non-ICM patients. Preoperative use of ICM was found to be significantly associated with decreased ER rates in both the primary cohort [odds ratio (OR) = 0.47, 95% confidence interval (CI) = 0.32–0.71; P < 0.001] and the matched cohort (OR = 0.48, 95% CI = 0.25–0.94; P = 0.031). Subgroup analysis on RAI delay time in the primary cohort revealed that ER rates in ICM patients were significantly lower than that of non-ICM patients for 1–2 months (P = 0.0245) and >2–3 months (P = 0.0221) subgroups, but not for >3–4 months, >4–5 months, and >5–6 months subgroups (all P > 0.05). A delay time of >3–4 months exhibited the highest ER rate (63.08%) within the ICM group.

Conclusions: Preoperative use of ICM is associated with decreased ER rates in intermediate-risk DTC patients who subsequently receive TT and low-dose RAI therapy. For such patients, if ICM has already been received, an RAI delay time of >3–4 months would seem to be more appropriate to achieve better ER rates.

Keywords: differentiated thyroid cancer, intravenous contrast media, radioactive iodine therapy, delay time, excellent response
INTRODUCTION

Post-operative use of radioactive iodine (RAI) continues to be conservative in differentiated thyroid cancer (DTC) patients with low to intermediate recurrence risk. While high dose is considered to be associated with dysfunctions in non-thyroidal organs such as salivary and lachrymal and long-term effects such as second primary cancer, plenty of studies have demonstrated that low dose is as effective as high dose in achieving ablation success and controlling disease recurrence in this patient population (1–3). However, delivering sufficient absorbed doses to the thyroid tissue is still important to ensure therapeutic efficacy.

Iodinated contrast media (ICM) is often used in DTC patients with locally aggressive disease or clinically apparent cervical lymph node to optimize preoperative planning and the completeness of surgery (4). Because ICM contains several 100-fold the recommended daily allowance of iodine and may cause a retention of iodine in the body for years (5, 6), there has long been a concern among nuclear medicine physicians that it could interfere with thyroid RAI uptake. Accordingly, in clinical practice, RAI administration was usually delayed for a certain period to eclipse this effect (7, 8). However, when a low-dose RAI protocol is applied, the interference of preoperative use of ICM may become significantly pronounced. It is possible that the patients’ clinical outcome and management strategy will be altered in this scenario.

Response-to-therapy assessment during the first 1–2 years after initial therapy for DTC patients is effective in estimating risk of long-term recurrence and was endorsed by the 2015 American Thyroid Association (ATA) guidelines (4). The most significant impact of this system is in patients with excellent response (ER), in whom the risk of disease recurrence was very low (1–4%), and far less intensive management would be required during follow-up. Thus, it is desirable to ensure that patients have a better chance of ER after RAI therapy.

In the present study, we evaluated whether the ER rates were influenced by preoperative use of ICM in the setting of a low-dose RAI protocol. Patients with initial ATA intermediate risk of recurrence were included, in whom the risk of recurrence is significant and in whom the impact of the response to therapy is most evident in terms of follow-up.

MATERIALS AND METHODS

Patients

The China-Japan Union Hospital is a tertiary-care University teaching center in northeastern China providing comprehensive care for thyroid cancer patients. All DTC patients in our center, except those with primary tumor measuring 1 cm or less confined to the thyroid gland, underwent total thyroidectomy (TT) with central or lateral neck dissection, depending on risk and intraoperative findings. From August 2016 on, the thyroid surgery department began to routinely select DTC patients to perform preoperative contrast CT following the 2015 ATA guidelines. However, because these guidelines also indicated that a 4–8-week interval between the use of ICM and RAI administration, which was defined as “RAI delay time” in this article, would be adequate to eclipse the impact of ICM on RAI absorption, the time interval before RAI administration was not controlled.

TABLE 1 | Protocol for RAI dosing.

| Risk stratification | Aim | Dose       |
|---------------------|-----|------------|
| Low and intermediate risk* | Remnant ablation | 1,110 MBq |
| High risk           | Adjuvant therapy | 3,700–5,550 MBq |
|                     | Therapy for persistent disease | 3,700–7,400 MBq |

*For patients with low risk of recurrence, RAI was administered based on patient’s preference, although the ATA guideline did not routinely recommend RAI therapy for these patients.

FIGURE 1 | Criteria of 2015 ATA intermediate-risk patients.
therapy, in our department, the RAI delay time for all patients (with or without ICM) in this period were solely determined by the patient's access to medical facilities and availability of RAI for administration.

We screened ATA intermediate-risk patients (detailed definition of intermediate risk in the 2015 ATA recurrence stratification system was shown in Figure 1) who had undergone TT and low-dose RAI therapy between August 2016 and August 2018. Patients who met the following criteria were excluded: (1) RAI delay time was more 6 months; (2) suspicion of distant metastases because of elevated serum ps-Tg level, radiological findings including chest computed tomography (CT), or positron emission tomography/CT, or therapeutic RAI scan, or histopathological biopsy; (3) positive or elevated serum Tg antibody (TgAb) level; and (4) patients with incomplete clinical data. Finally, a total of 683 patients were retrospectively enrolled. The study was approved by the local ethics committee.

Preoperative ICM and Measurement of Preablation Urinary Iodine Concentration

Preoperative ICM included iodixanol, iohexol, and iopromide, which are all non-ionic and have an iodine concentration of 320, 350, and 370 mg/mL, respectively. The ICM dose administered was 100 mL for iodixanol or iohexol and 80–100 mL for iopromide per CT scan.

Preablation urinary iodine (UI) concentration was measured using a rapid kit (Zhongsheng Jinyu Diagnostic Technology Company Limited, Beijing, China) developed based on the study of Rendl et al. (9, 10). After sample collection (between 8 and 11 AM), measurement was done within 2 h according to manufacturer's protocol.

RAI Protocol

Patients were prepared by levothyroxine (LT4) withdrawal together with a strict low-iodine diet for at least 2 weeks, with the goal of attaining an appropriate thyroid-stimulating

| TABLE 2 | Patients’ baseline characteristics. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| | Primary cohort (n = 683) | Matched cohort (n = 186) | | |
| | Non-ICM (n = 532) | ICM (n = 151) | P-value | Non-ICM (n = 93) | ICM (n = 93) | P-value |
| Age at diagnosis [n (%)] | 41.5 ± 14.8 | 41.5 ± 13.0 | 0.989 | 38.8 ± 13.9 | 42.1 ± 13.6 | 0.105 |
| Gender [n (%)] | | | | | | |
| Female | 362 (68.0%) | 93 (61.6%) | 0.138 | 66 (71.0%) | 58 (62.4%) | 0.213 |
| Male | 170 (32.0%) | 58 (38.4%) | | 27 (29.0%) | 35 (37.6%) | |
| Multifocality [n (%)] | | | | | | |
| No | 230 (43.2%) | 57 (37.7%) | 0.228 | 41 (44.1%) | 37 (39.6%) | 0.552 |
| Yes | 302 (56.8%) | 94 (62.3%) | | 52 (55.9%) | 56 (60.2%) | |
| T stage [n (%)] | | <0.001 | | 0.069 |
| T1 | 335 (63.0%) | 55 (36.4%) | | 47 (50.5%) | 55 (59.1%) | |
| T2 | 86 (16.2%) | 2 (1.3%) | | 9 (9.7%) | 1 (1.1%) | |
| T3 | 94 (17.7%) | 80 (53.0%) | | 28 (30.1%) | 29 (31.2%) | |
| T4 | 17 (3.2%) | 14 (9.3%) | | 9 (9.7%) | 8 (8.6%) | |
| N stage [n (%)] | | <0.001 | | 0.247 |
| N0 | 86 (16.2%) | 7 (4.6%) | | 5 (5.4%) | 7 (7.5%) | |
| N1a | 347 (65.2%) | 31 (20.5%) | | 42 (45.2%) | 31 (33.3%) | |
| N1b | 99 (18.6%) | 113 (74.8%) | | 46 (49.5%) | 55 (59.1%) | |
| Delay time [n (%)] | | 0.742 | | 0.883 |
| 1–2 months | 100 (18.8%) | 27 (17.9%) | | 14 (15.1%) | 18 (19.4%) | |
| 2–3 months | 211 (39.7%) | 54 (35.8%) | | 35 (37.6%) | 31 (33.3%) | |
| 3–4 months | 97 (18.2%) | 33 (21.9%) | | 16 (17.2%) | 18 (19.4%) | |
| 4–5 months | 82 (15.4%) | 22 (14.6%) | | 19 (20.4%) | 16 (17.2%) | |
| 5–6 months | 42 (7.9%) | 15 (9.9%) | | 9 (9.7%) | 10 (10.8%) | |
| Histologic subtype [n (%)] | | 0.980 | | 0.601 |
| Papillary | 500 (94.0%) | 142 (94.0%) | | 86 (92.5%) | 84 (90.3%) | |
| Follicular | 32 (6.0%) | 9 (6.0%) | | 7 (7.5%) | 9 (9.7%) | |
| T39m-Tc-pertechnetate uptake [n (%)] | | 0.187 | | 0.240 |
| Negative | 253 (47.6%) | 81 (53.6%) | | 40 (43.0%) | 48 (51.6%) | |
| Positive | 279 (52.4%) | 70 (46.4%) | | 53 (57.0%) | 45 (48.4%) | |
| TSH (mIU/mL), mean | 103.6 ± 34.9 | 99.1 ± 28.1 | | 101.1 ± 34.3 | 100.5 ± 28.5 | 0.896 |
| Ps-Tg (ng/mL), mean | 4.3 ± 4.2 | 5.1 ± 4.6 | 0.042 | 4.6 ± 4.2 | 5.6 ± 4.7 | 0.122 |
| UI (µg/L), mean | 82.9 ± 30.9 | 96.5 ± 32.1 | <0.001 | 95.6 ± 36.0 | 91.1 ± 30.4 | 0.356 |
hormone (TSH) level > 30 µIU/mL. Patients who were scheduled to perform an imminent RAI therapy should have a UI concentration of < 200 µg/L. The RAI dose administered was based on the 2015 ATA guidelines according to TNM stage and recurrence risk stratification. For intermediate-risk patients included in this study, a fixed low-dose RAI was administered for successful remnant ablation (Table 1 shows the protocol for RAI dosing in our department). Thyroxine therapy was resumed on the third day, and a therapeutic RAI scan was performed 3–5 days after RAI therapy.

**Response Assessment**

Response assessment was performed 16–40 months after RAI therapy. In this study, the response was divided into ER and NER according to the serological examination (suppressed Tg, stimulated Tg, and TgAb) and imaging technique (DxWBS, cervical ultrasound, chest CT, and bone scintigraphic imaging) described in the 2015 ATA guidelines. Excellent response was defined as negative imaging and at the same time either suppressed Tg up to 0.2 ng/mL or ps-Tg up to 1 ng/mL with the absence of TgAb.

**Statistical Analysis**

We utilized propensity score methods to adjust for difference in the baseline characteristics of patients in the ICM and non-ICM groups. To estimate the propensity score, logistic regression was performed with three variables: T stage, N stage, and UI (all \( P < 0.001 \) in univariate analyses). After propensity score estimation, the ICM and non-ICM groups were matched according to propensity score in a 1:1 ratio with a caliper of 0.05. Univariate

---

**TABLE 3 | Factors associated with the excellent response.**

|                  | Primary cohort (n = 683) | Matched cohort (n = 186) |
|------------------|--------------------------|--------------------------|
|                  | NER (n = 256) | ER (n = 427) | P-value | NER (n = 81) | ER (n = 105) | P-value |
| ICM [n (%)]      |               |               | 0.011   |               |               | 0.183   |
| No               | 186 (72.7%)   | 346 (81.0%)   |         | 36 (44.4%)   | 57 (54.3%)   |         |
| Yes              | 70 (27.3%)    | 81 (19.0%)    |         | 45 (55.6%)   | 48 (45.7%)   |         |
| Age at diagnosis (years), mean | 41.0 ± 15.1 | 41.8 ± 14.0 | 0.462   | 39.3 ± 14.4 | 41.3 ± 13.3 | 0.344   |
| Gender [n (%)]   |               |               | 0.360   |               |               | 0.530   |
| Female           | 176 (68.8%)   | 279 (65.3%)   |         | 52 (64.2%)   | 72 (68.6%)   |         |
| Male             | 80 (31.2%)    | 148 (34.7%)   |         | 29 (35.8%)   | 33 (31.4%)   |         |
| Multifocality [n (%)] |               |               | 0.372   |               |               | 0.074   |
| No               | 102 (39.8%)   | 185 (43.3%)   |         | 28 (34.6%)   | 50 (47.6%)   |         |
| Yes              | 154 (60.2%)   | 242 (56.7%)   |         | 53 (65.4%)   | 55 (52.4%)   |         |
| T stage [n (%)]  |               |               | 0.968   |               |               | 0.24    |
| T1               | 146 (57.0%)   | 244 (57.1%)   |         | 51 (63.0%)   | 51 (48.6%)   |         |
| T2               | 32 (12.5%)    | 56 (13.1%)    |         | 4 (4.9%)     | 6 (5.7%)     |         |
| T3               | 65 (25.4%)    | 109 (25.5%)   |         | 21 (25.9%)   | 36 (34.3%)   |         |
| T4               | 13 (5.1%)     | 18 (4.2%)     |         | 5 (6.2%)     | 12 (11.4%)   |         |
| N stage [n (%)]  |               |               | 0.194   |               |               | 0.664   |
| N0               | 32 (12.5%)    | 61 (14.3%)    |         | 5 (6.2%)     | 7 (6.7%)     |         |
| N1a              | 134 (52.3%)   | 244 (57.1%)   |         | 29 (35.8%)   | 44 (41.9%)   |         |
| N1b              | 90 (35.2%)    | 122 (28.6%)   |         | 47 (58.0%)   | 54 (51.4%)   |         |
| Delay time [n (%)] |               |               | 0.175   |               |               | 0.954   |
| 1–2 months       | 47 (18.4%)    | 80 (18.7%)    |         | 16 (19.8%)   | 16 (15.2%)   |         |
| 2–3 months       | 88 (34.4%)    | 177 (41.5%)   |         | 28 (34.6%)   | 38 (36.2%)   |         |
| 3–4 months       | 48 (18.8%)    | 82 (19.2%)    |         | 14 (17.3%)   | 20 (19.0%)   |         |
| 4–5 months       | 47 (18.4%)    | 57 (13.3%)    |         | 15 (18.5%)   | 20 (19.0%)   |         |
| 5–6 months       | 26 (10.2%)    | 31 (7.3%)     |         | 8 (9.9%)     | 11 (10.5%)   |         |
| Histologic subtype [n (%)] |               |               | 0.833   |               |               | 0.986   |
| Papillary        | 240 (93.8%)   | 402 (94.1%)   |         | 74 (91.4%)   | 96 (91.4%)   |         |
| Follicular       | 16 (6.2%)     | 25 (5.9%)     |         | 7 (8.6%)     | 9 (8.6%)     |         |
| 99mTc-pertechnetate uptake [n (%)] | <0.001 | <0.001 |         |
| Negative         | 99 (38.7%)    | 235 (55.0%)   |         | 28 (34.6%)   | 60 (57.1%)   |         |
| Positive         | 157 (61.3%)   | 192 (45.0%)   |         | 53 (65.4%)   | 45 (42.9%)   |         |
| TSH (µIU/mL), mean | 102.8 ± 33.7 | 102.5 ± 33.5 | 0.916   | 101.2 ± 34.0 | 100.5 ± 29.5 | 0.878   |
| Ps-Tg (ng/mL), mean | 7.2 ± 4.9   | 3.6 ± 3.6     | <0.001  | 7.0 ± 4.5    | 3.8 ± 3.8    | <0.001  |
| UI (µg/L), mean  | 86.7 ± 29.5  | 85.4 ± 32.9   | 0.172   | 91.9 ± 30.2  | 94.5 ± 35.6  | 0.596   |
analyses were performed to compare the clinical characteristics of the patients and ER rates between the two groups. To evaluate the impact of preoperative use of ICM on ER rates, non-adjusted, risk-adjusted, and fully adjusted logistic regression models were constructed for the both primary and the matched cohort. For risk-adjusted analyses, we adjusted for features that were significant in the univariate analyses. The subgroup analyses were performed using R × C χ² test. Categorical variables were compared with either χ² test or Fisher exact test as appropriate. Student t-test was used for normally distributed continuous variables, and the Mann-Whitney U-test was used for non-normally distributed continuous variables. Statistical analysis was performed using R software (version 3.4.3; http://www.R-project.org, The R Foundation). P < 0.05 was considered to indicate statistical significance.

RESULTS

Patients

For the included patients, five hundred and thirty-two of them underwent preoperative ICM and 151 did not. Patients' baseline characteristics are shown in Table 2. As can be seen, T stage (P < 0.001), N stage (P < 0.001), UI (P < 0.001), and ps-Tg (P = 0.042) in the ICM group were significantly higher than that of the non-ICM group. After propensity score matching, 93 pairs of patients in the ICM group were significantly higher than those of the non-ICM group either in the primary cohort (53.6 vs. 65.0%) or in the matched cohort (45.7 vs. 54.3%).

In univariate analyses, for the primary cohort, significant difference was found between ER group and non-ER group (45.7 vs. 54.3%). In multivariate analyses, the use of ICM (P = 0.011), ⁹⁹mTc-pertechnetate uptake (P < 0.001) and ps-Tg (P < 0.001); for the matched cohort, significant difference was found between the ER group and non-ER group for the use of ICM (P = 0.011), ⁹⁹mTc-pertechnetate uptake (P = 0.002), and ps-Tg (P < 0.001) (Table 3). In multivariate analyses, the use of ICM was found to be significantly associated with decreased ER rates in crude model [odds ratio (OR) = 0.61, 95% confidence interval (CI) = 0.43–0.90, P = 0.011, in the primary cohort; and OR = 0.67, 95% CI = 0.38–1.21, P = 0.184, in the matched cohort], risk-adjusted model (OR = 0.47, 95% CI = 0.32–0.71, P < 0.001, in the primary cohort; and OR = 0.48, 95% CI = 0.25–0.94, P = 0.031, in the matched cohort), and fully adjusted model (OR = 0.48, 95% CI = 0.29–0.80, P = 0.005, in the primary cohort; and OR = 0.51, 95% CI = 0.25–1.04, P = 0.065, in the matched cohort) (Table 4).

Impact of Preoperative Use of ICM on ER Rates

The distribution of ER rates for the ICM patients and the non-ICM patients is shown in Table 3. Excellent response rates in the ICM group were lower than those of the non-ICM group either in the primary cohort (53.6 vs. 65.0%) or in the matched cohort (45.7 vs. 54.3%).

In univariate analyses, for the primary cohort, significant difference was found between ER group and non-ER group for 1–2 months (P = 0.005) and >2–3 months (P = 0.011).

Subgroup Analysis on RAI Delay Time

The RAI delay time of the 683 patients were categorized into five subgroups, and the number of patients in each group can be seen in Table 2. In the primary cohort, the ER rates in ICM patients were significantly lower than those of non-ICM patients for 1–2 months (P = 0.0245) and >2–3 months (P = 0.0221).
subgroups, but not for >3–4 months, >4–5 months, and >5–6 months subgroups (All \( P > 0.05 \)) (Table 5).

**Relationship Between UI Concentration and Clinical Outcomes**

In univariate and multivariate analyses, UI concentration was found to be not associated with ER rates for either the primary or the matched cohort (All \( P > 0.05 \)). Table 6 shows UI concentration according to clinical outcomes for the five RAI delay time subgroups in the primary cohort. Still, no association between UI concentration and ER rates was found within each of the five subgroups (All \( P > 0.05 \)).

**DISCUSSION**

The 2015 ATA guidelines assumed that the use of ICM should not be a major concern for RAI therapy as long as 4–8 weeks’ delay time was fulfilled (4). However, this arbitrary cutoff was only inferred based on the clearance time of UI values (11–13). It is unclear whether these values accurately reflect free iodide accumulation by thyroid tissue. Moreover, in a recent study, Vassaux et al. suggested that independent of free iodide, the ICM itself could directly reduce thyroid iodide uptake by decreasing NIS expression in thyroid cells. Besides, they found that ICM induces thyroid stunning to a greater and longer-lasting degree than free iodide found in ICM could explain (14). Thus, the influence of the use of ICM might have been stronger and more enduring than we previously thought. Nevertheless, although the interference of ICM on thyroid RAI uptake is well-documented in the literature (15), as far as we know, there have been no previous studies to directly and systemically evaluate the impact of preoperative use of ICM on patients’ clinical outcome after RAI therapy.

In the present study, by analyzing a large cohort of intermediate-risk patients in the setting of a low-dose RAI protocol, which our department had been implementing since August 2015 (16), we evaluated whether preoperative use of ICM significantly impacted the ER rates. We chose ER rates as a clinical endpoint in this study, because in intermediate-risk patients, ER decreases the estimated risk of recurrence from 20 to 30% to < 5%, leading to less intensive follow-up and no need for TSH suppression (17). Propensity score matching was performed to balance the confounding factors in the primary cohort. In multivariate analysis, we found that the use of ICM was significantly associated with decreased ER rates in non-adjusted, risk-adjusted, and fully adjusted models for either the primary or the matched cohort. This implies that the use of ICM has a significant negative impact in terms of patients’ clinical outcome, although it might help to improve evaluation of tissue planes and detection of local invasion before surgery. Thus, the negative

![FIGURE 2](Changes of ER rates as RAI delay time extends in both ICM and non-ICM patients.)
impact of ICM on RAI therapy cannot be ignored in this scenario, and decision making of the use of ICM should at least take into account whether the patients are likely to receive low-dose RAI therapy afterward. To go a step further, withholding ICM might be an option in patients with lower tumor burden. As a matter of fact, toward the necessity of preoperative use of ICM, many scholars have already argued that CT without ICM can provide sufficient information regarding tumor and vascular and aerodigestive structures for effective surgical planning (18).

In a subgroup analysis on RAI delay time, we showed that in the primary cohort ER rates in ICM patients were significantly lower than that of non-ICM patients for 1–2 months \((P = 0.0245)\) and \(> 2–3\) months \((P = 0.0221)\) subgroups, but not for \(> 3–4\) months, \(> 4–5\) months, and \(> 5–6\) months subgroups \((\text{All } P > 0.05)\). This indicated that the would-be negative impact of ICM on RAI therapy might persist until 3 months after surgery. In other words, if the patients had received contrast CT, the RAI delay time should be at least more than 3 months for the ICM not to significantly influence ER rates. Moreover, the RAI delay time itself is believed to impact RAI therapy, and longer delay time usually correlates with worse clinical outcome (19, 20). In our ICM group, the ER rates showed a first increased and then decreased trend among the five delay time subgroups, with the \(> 3–4\) months subgroup exhibiting the highest (Figure 2). It could be speculated that this time period might be able to better balance the decreasing negative impact of ICM and the increasing negative impact of delay time itself on RAI therapy. Thus, an RAI delay time of \(> 3–4\) months seems to be more appropriate for patients to achieve better ER rates in this scenario.

Urinary iodine is an easily obtainable indicator for iodine status and a sensitive marker of iodine intake and changes in iodine status. Previously, several researchers concluded that 1-month delay is sufficient for ICM patients to perform RAI therapy because UI concentration could return to baseline values \((\text{before the use of ICM})\) during this period (11, 12). However, in our study, although the UI concentrations of all included patients were within normal range \((< 200 \mu g/L)\) before RAI therapy, it was found to be not associated with the clinical outcome for either the primary or the matched cohort or within each of the five RAI delay time subgroups in the primary cohort. These results indicated that UI concentration within normal range cannot guarantee the absence of interference from ICM in terms of clinical outcome. This was in accordance with the theory proposed by Vassaux et al. (14) in \textit{in vitro} studies as mentioned previously. Therefore, our study demonstrated in a clinical practice setting that it might be not suitable for using a “normal UI concentration” to decide the initiation of RAI therapy if the patients had received preoperative ICM.

There are some limitations to this study. First, it was a retrospective study performed in a single institution. Although propensity score matching was used to minimize the effect of observed confounders, it cannot address unobserved confounders. For example, preoperative contrast CT was performed at the surgeons’ discretion after seeing the result of the neck ultrasound. This could have already led to selection bias. In this regard, a multi-institutional prospective randomized trial with a larger number of patients would be more appropriate. Second, the follow-up duration in our study is relatively short, and continued observations are still needed to evaluate long-term clinical outcomes. Lastly, we used a rapid UI test method that is not completely quantitative, and rather than a period of 24 h, only single-spot urine was collected. These might undermine the results derived from UI concentration in our study.

**CONCLUSIONS**

Preoperative use of ICM is associated with decreased ER rates in intermediate-risk DTC patients who subsequently receive TT and low-dose RAI therapy. For such patients, if ICM has already been received, an RAI delay time of \(> 3–4\) months would seem to be more appropriate to achieve better ER rates.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by ethics committee of China-Japan Union Hospital. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

JB, MQ, and WL conceived and designed the study. WL, WR, WQ, and TF performed the retrospective study. WR and WQ interpreted the data. WL and JB wrote the paper. JB and MQ supervised the study, reviewed, and edited the manuscript. All authors approved the final manuscript.

**REFERENCES**

1. Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes Endocrinol. (2019) 7:44–51. doi: 10.1016/S2213-8587(18)30306-1

2. Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C, et al. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. Eur J Endocrinol. (2013) 169:23–9. doi: 10.1530/EJE-12-0954

3. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. (2012) 366:1674–85. doi: 10.1056/NEJMoa1109589

4. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. (2016) 26:1–133. doi: 10.1089/thy.2015.0020
5. Costa A, Testori OB, Cenderelli C, Giribone G, Migliardi M. Iodine content of human tissues after administration of iodine containing drugs or contrast media. *J Endocrinol Invest.* (1978) 1:221–5. doi: 10.1007/BF03350384

6. Burman KD, Wartofsky L. Iodine effects on the thyroid gland: biochemical and clinical aspects. *Rev Endocr Metab Disord.* (2000) 1:19–25. doi: 10.1007/A1010004218052

7. Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. *The SNMMI practice guideline for therapy of thyroid disease with 131I.* *J Nucl Med.* (2012) 53:1633–51. doi: 10.2967/jnumed.112.105148

8. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. *Guidelines for radioiodine therapy of differentiated thyroid cancer.* *Eur J Nucl Med Mol Imaging.* (2008) 35:1941–59. doi: 10.1007/s00259-008-0883-1

9. Rendl J, Bier D, Groh T, Reiners C. Rapid urinary iodide test. *J Clin Endocrinol Metab.* (1998) 83:1007–12. doi: 10.1210/jcem.83.3.4633

10. Shao HJ, Li J, He XQ, Liu N, Li YH, Yan JJ, et al. Prevalence of nontoxic nodular goiter after a nearly two-decade universal salt iodization in a littoral region of shandong province, China. *Acta Endocrinol.* (2016) 12:43–6. doi: 10.4183/aeb.2016.43

11. Padovani RP, Kasamatsu TS, Nakabashi CC, Camacho CP, Andreoni DM, Malouf EZ, et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water-soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy. *Thyroid.* (2012) 22:926–30. doi: 10.1089/thy.2012.0099

12. Sohn SY, Choi JH, Kim NK, Joung JY, Cho YY, Park SM, et al. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment. *Thyroid.* (2014) 24:872–7. doi: 10.1089/thy.2013.0238

13. Mishra A, Pradhan PK, Gambhir S, Sabaretnam M, Gupta A, Babu S. Preoperative contrast-enhanced computerized tomography should not delay radiiodine ablation in differentiated thyroid carcinoma patients. *J Surg Res.* (2015) 193:731–7. doi: 10.1016/j.jss.2014.07.065

14. Vassaux G, Zwarthoed C, Signetti L, Guglielmi J, Compin C, Guigonis JM, et al. Iodinated contrast agents perturb iodide uptake by the thyroid independently of free iodide. *J Nucl Med.* (2016) 59:121–6. doi: 10.2967/jnumed.117.195685

15. Laurie AJ, Lyon SG, Lasser EC. Contrast material iodides: potential effects on radioactive iodine thyroid uptake. *J Nucl Med.* (1992) 33:237–8.

16. Lan W, Geze Z, Ningning L, Qiang W, Lin B, Qingjie M, et al. Negative remnant (99m)Tc-pertechnetate uptake predicts excellent response to radioactive iodine therapy in low- to intermediate-risk differentiated thyroid cancer patients who have undergone total thyroidectomy. *Ann Nucl Med.* (2019) 33:112–8. doi: 10.1007/s12149-018-1314-4

17. Moreno I, Hirsch D, Duskin-Bitan H, Dicker-Cohen T, Shimon I, Robenshtok E. Response to therapy assessment in intermediate-risk thyroid cancer patients: is thyroglobulin stimulation required? *Thyroid.* (2020) 30:863–70. doi: 10.1089/thy.2019.0431

18. Luster M, Aktolun C, Amendoeira I, Barczynski M, Bible KC, Duntas LH, et al. European perspective on 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: proceedings of an interactive international symposium. *Thyroid.* (2019) 29:7–26. doi: 10.1089/thy.2017.0129

19. Li H, Zhang YQ, Wang C, Zhang X, Li X, Lin YS. Delayed initial radioiodine therapy related to incomplete response in low- to intermediate-risk differentiated thyroid cancer. *Clin Endocrinol.* (2018) 88:601–6. doi: 10.1111/cen.13551

20. Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, et al. Delayed initial radioiodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. *J Nucl Med.* (2011) 52:683–9. doi: 10.2967/jnumed.110.081059

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Lan, Renjie, Qichang, Feiyue, Qingjie and Bin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.